Enanta Pharmaceuticals, Inc. (ENTA) Social Stream

Featured Post From StockTwits About ENTA

$ENTA New Press Release:

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-721, a novel, oral hepatitis B virus (HBV) RNA destabilizer being developed for use in an all-oral combination regimen for chronic HBV patients. “We are pleased to advance our HBV program by dosing the first subject in our Phase 1 clinical st (...)

https://wchr.one/114238